EN DE

NexturnBioscience Co. Ltd (089140) Fair Value & Analysis

Industrials · KR · Market cap 34.0B KRW

NC NexturnBioscience Co. Ltd 089140 · KQ
Price2,275 KRW
Fair Value1,790 KRW
Upside-21.3%
Quality26/100
Watch NexturnBioscience Co. Ltd for free, get notified when fair value or trend changes. Watch for free
Expensive Growth
Thin margins · 9.8% net margin
Low debt · negative free cash flow
Trails peers (2/7)
Narrow moat 21/100
Evidence: Low Range 1,660 KRW – 1,790 KRW Share as image

Fair value as of: Aug 13, 2026

From 6 valuation models · updated 6 days ago

Share price +5.8% over the past month.

Below-average quality, and screening another 21% overvalued on our models.

What matters now

  • The price sits above even our optimistic bull case (1,790 KRW). The favourable scenario is already priced in.
  • Weak quality (26/100) and above fair value at the same time, the margin of safety is missing on both counts.
  • The models converge in a tight band (1,660 KRW to 1,790 KRW), unusually little disagreement for a valuation.
  • Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.
Share this valuation: 𝕏 WhatsApp

Price vs Fair Value (5 years)

56,500 KRW 1,853 KRW Fair Value 1,790 KRW Mar 2021 Aug 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 13, 2026.

How to read this chart

60‑month range 1,853 KRW – 56,500 KRW · fair‑value band 1,660 KRW – 1,790 KRW · the 2,275 KRW price screens above the 1,790 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Aug 13, 2026.

Full chart & analysis →

Which stocks are undervalued right now? Check free Discover now →

Analysis

NexturnBioscience Co. Ltd (089140) currently trades at 2,275 KRW, while our model-based Fair Value estimate is 1,790 KRW, implying the stock looks roughly 21.3% overvalued today. The Quality Score stands at 26/100 (below-average quality), in the Industrials sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: low).

Over the trailing twelve months, NexturnBioscience Co. Ltd generated revenue of 20.5B KRW at a net margin of 9.8%. Revenue grew 237.3% year over year. Net debt stands at 74.5B KRW. Fundamentals as of Aug 13, 2026

Our scenario range runs from 1,660 KRW (bear case) to 1,790 KRW (bull case); at 2,275 KRW, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 30% below its 52-week high and 16% above its 52-week low, currently below its 200-day average. For context, the median of 10 Industrials peers we cover trades at -13% fair-value upside, at -21%, 089140 screens richer than that median.

Fair Value models

Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.

Model Bear Bear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull Bull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence
Highest evidence
ROIC Compounder 2,088 KRW 2,286 KRW 2,459 KRW 72
EPV 2,088 KRW 2,286 KRW 2,459 KRW 59
EV/EBITDA 4,374 KRW 5,531 KRW 6,688 KRW 54
All 6 models by family
Earnings-Based
EPV 2,088 KRW 2,286 KRW 2,459 KRW 59
Multiples
EV/EBIT 2,863 KRW 3,516 KRW 4,170 KRW 53
EV/EBITDA 4,374 KRW 5,531 KRW 6,688 KRW 54
EV/Revenue 2,301 KRW 2,901 KRW 3,501 KRW 43
Asset-Based
NCAV (Graham) 4,531 KRW 6,071 KRW 9,061 KRW 50
Economic Profit
ROIC Compounder 2,088 KRW 2,286 KRW 2,459 KRW 72

Widest divergence: Asset-Based (6,071 KRW) versus Earnings-Based (2,286 KRW). Highest evidence: ROIC Compounder (72).

Notify me when 089140 reaches fair value

Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.

Key figures & financial health

Revenue (TTM) 20.5B KRW
Revenue growth (YoY) +237%
Net margin 9.8%
Return on equity -1,091%
Free cash flow −6.2B KRW FY2025
Operating margin -16.8%
More key figures
EPS growth (YoY) -11.3%
Net debt 74.5B KRW FY2025

Figures from reported company fundamentals · as of Aug 13, 2026. TTM = trailing twelve months.

Quality Score breakdown

Overall quality 26/100

Of which business quality 25 · Market factors (momentum, volatility) 30

Profitability 5
Margins and returns on capital today
Quality Growth 91
Are margins and returns improving?
Cashflow 0
Earnings quality: real cash, not paper profit
Fin. Strength 28
Balance sheet, leverage, solvency risk
Investment 55
Disciplined investing over empire-building
Low Volatility 20
Calm price path (market factor)
Momentum 36
Price trend over the last 3–12 months (market factor)
52W Momentum 30
Distance to the 52-week high (market factor)
Net Issuance 0
Buybacks instead of dilution

Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.

About the company

Nexturn Co.,Ltd. develops and produces CNC automatic lathe machines in Korea and internationally. It provides CNC swiss-type automatic lathe products, high temperature display glass press equipment, and automatic line-up robots, as well as an intelligent intervention robot system based on robot 3D cardiovascular visualization technology.

Full company description

Nexturn Co.,Ltd. develops and produces CNC automatic lathe machines in Korea and internationally. It provides CNC swiss-type automatic lathe products, high temperature display glass press equipment, and automatic line-up robots, as well as an intelligent intervention robot system based on robot 3D cardiovascular visualization technology. The company was formerly known as KMT Incorporated and changed its name to Nexturn Co.,Ltd. in April 2004. Nexturn Co.,Ltd. was founded in 2000 and is based in Yongin, South Korea.

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

NexturnBioscience Co. Ltd reported revenue of 70.4B KRW in FY2025 versus 17.0B KRW in FY2021, a compound +42.7%/yr. Reported net income was −9.7B KRW in FY2025.

Growth Quality 58/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Latest Revenue (FY 2025)
70.4B KRW
Latest YoY
+122.6%
Avg. growth/yr (3Y) Measures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+44.3%
Avg. growth/yr (5Y) Measures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+48.7%
Avg. growth/yr (11Y) Measures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+11.9%
Revenue +42.7%/yr
FY21 17.0B KRW
FY22 23.5B KRW
FY23 41.3B KRW
FY24 31.6B KRW
FY25 70.4B KRW
Net income
FY21 −4.4B KRW
FY22 −4.7B KRW
FY23 9.7B KRW
FY24 −13.0B KRW
FY25 −9.7B KRW

089140 screens 21% overvalued. Compare with NIBE Industrier AB →

Share or link this analysis
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Cite: Fair Value Calculator (2026). "NexturnBioscience Co. Ltd Fair Value". https://www.fairvalue-calculator.com/stock/089140

Peer Group

Machinery, Tools, Heavy Vehicles, Trains & Ships · 37 stocks

How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.

Quality Score 26 · Bottom 25%
Fair Value upside −21% · Below median
Return on assets -1% · Bottom 25%
Net margin (TTM) 10% · Above median
Operating margin (TTM) -17% · Bottom 25%
Revenue growth 237% · Top 25%
Debt / equity 0.05× · Higher than median

Snowflake

Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE5 · sector 32
FUTURE100 · sector 62
PAST0 · sector 100
HEALTH98 · sector 99
DIVIDEND0 · sector 35

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.

Similar stocks

10 more Machinery, Tools, Heavy Vehicles, Trains & Ships stocks, each showing price versus our Fair Value estimate (as of Aug 13, 2026).

Stock Price Fair Value vs Fair Value
NIBE Industrier AB NIBEB CHF 3.33 CHF 2.28 -32%
505790 505790 ₹4,044 ₹8,002 +98%
BHI Co 083650 56,500 KRW 43,356 KRW -23%
VITZROCELL Co 082920 34,150 KRW 23,575 KRW -31%
Sungho Electronics Corp 043260 19,930 KRW 17,261 KRW -13%
SKF India Limited 500472 ₹1,532 ₹695.28 -55%
506076 506076 ₹2,164 ₹2,741 +27%
Hyulim ROBOT Co 090710 7,720 KRW 1,053 KRW -86%
Blue Star Limited 500067 ₹1,510 ₹3,534 +134%
Tae Kwang Corporation 023160 23,200 KRW 24,471 KRW +5%

Compare NexturnBioscience Co. Ltd with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Explore undervalued stocks

More undervalued Industrials stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Frequently asked questions

Is NexturnBioscience Co. Ltd (089140) overvalued or undervalued?
As of Aug 13, 2026, our model estimates a fair value of 1,790 KRW versus a price of 2,275 KRW, about −21% (overvalued).
What is the fair value of 089140?
Our model-based fair value for NexturnBioscience Co. Ltd is 1,790 KRW (as of Aug 13, 2026), built from audited fundamentals. The current price: 2,275 KRW.
What is the quality score of 089140?
NexturnBioscience Co. Ltd has a Quality Score of 26/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the revenue of NexturnBioscience Co. Ltd (089140)?
NexturnBioscience Co. Ltd reported trailing-twelve-month revenue of about 20.5B KRW (latest available figure, as of Aug 13, 2026).
What is the net profit margin of 089140?
The net profit margin of NexturnBioscience Co. Ltd is about 9.8%, meaning it keeps roughly 9.8% of revenue as net income. Based on the latest reported figures.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.

14 days Pro free · no card

Track NexturnBioscience Co. Ltd and try Pro for 14 days

One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.

Zero risk: nothing is ever charged. After 14 days you decide whether to stay.